Torén K, Bake B, Olin A-C, Engström G, Blomberg A, Vikgren J, Hedner J, Brandberg J, Persson H L, Sköld C M, Rosengren A, Bergström G, Janson C
Section of Occupational and Environmental Medicine, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg.
Department of Clinical Science, Lund University, Malmö.
Int J Chron Obstruct Pulmon Dis. 2017 Mar 22;12:973-980. doi: 10.2147/COPD.S127336. eCollection 2017.
Data are lacking from general population studies on how to define changes in lung function after bronchodilation. This study aimed to analyze different measures of bronchodilator response of forced expiratory volume in 1 second (FEV), forced vital capacity (FVC) and slow vital capacity (SVC).
Data were derived from the Swedish Cardiopulmonary Bioimage Study (SCAPIS) Pilot study. This analysis comprised 1,050 participants aged 50-64 years from the general population. Participants were investigated using a questionnaire, and FEV, FVC and SVC were recorded before and 15 minutes after inhalation of 400 µg of salbutamol. A bronchodilator response was defined as the relative change from baseline value expressed as the difference in units of percent predicted normal. Predictors of bronchodilator responses were assessed using multiple linear regression models. Airway obstruction was defined as FEV/FVC ratio below lower limit of normal (LLN) before bronchodilation, and COPD was defined as an FEV/FVC ratio below LLN after bronchodilation. Physician-diagnosed asthma was defined as an affirmative answer to "Have you ever had asthma diagnosed by a physician?". Asymptomatic never-smokers were defined as those not reporting physician-diagnosed asthma, physician-diagnosed COPD or emphysema, current wheeze or chronic bronchitis and being a lifelong never-smoker.
Among all subjects, the greatest bronchodilator responses (FEV, FVC and SVC) were found in subjects with asthma or COPD. The upper 95th percentile of bronchodilator responses in asymptomatic never-smokers was 8.7% for FEV, 4.2% for FVC and 5.0% for SVC. The bronchodilator responses were similar between men and women. In a multiple linear regression model comprising all asymptomatic never-smokers, the bronchodilator response of FEV was significantly associated with airway obstruction and height.
When the bronchodilator response in asymptomatic never-smokers is reported as the difference in units of predicted normal, significant reversibility of FEV, FVC and SVC to bronchodilators is ~9%, 4% and 5%, respectively.
关于如何定义支气管扩张后肺功能变化,一般人群研究缺乏相关数据。本研究旨在分析一秒用力呼气容积(FEV)、用力肺活量(FVC)和慢肺活量(SVC)的支气管扩张剂反应的不同测量指标。
数据来源于瑞典心肺生物影像研究(SCAPIS)试点研究。该分析纳入了1050名年龄在50 - 64岁的一般人群参与者。参与者通过问卷调查进行调查,并在吸入400μg沙丁胺醇之前和之后15分钟记录FEV、FVC和SVC。支气管扩张剂反应定义为相对于基线值的相对变化,以预测正常百分比单位的差异表示。使用多元线性回归模型评估支气管扩张剂反应的预测因素。气道阻塞定义为支气管扩张前FEV/FVC比值低于正常下限(LLN),慢性阻塞性肺疾病(COPD)定义为支气管扩张后FEV/FVC比值低于LLN。医生诊断的哮喘定义为对“您是否曾被医生诊断为哮喘?”的肯定回答。无症状从不吸烟者定义为未报告医生诊断的哮喘、医生诊断的COPD或肺气肿、当前喘息或慢性支气管炎且为终身从不吸烟者。
在所有受试者中,哮喘或COPD患者的支气管扩张剂反应(FEV、FVC和SVC)最大。无症状从不吸烟者中支气管扩张剂反应的第95百分位数上限为FEV 8.7%、FVC 4.2%和SVC 5.0%。男性和女性的支气管扩张剂反应相似。在包含所有无症状从不吸烟者的多元线性回归模型中,FEV的支气管扩张剂反应与气道阻塞和身高显著相关。
当将无症状从不吸烟者的支气管扩张剂反应报告为预测正常单位的差异时,FEV、FVC和SVC对支气管扩张剂的显著可逆性分别约为9%、4%和5%。